Literature DB >> 3631919

Factors that influence the occurrence of response variations in Parkinson's disease.

G J de Jong, J D Meerwaldt, P I Schmitz.   

Abstract

Retrospective study of 129 patients treated with dopamine substitution showed that the occurrence of response variations is related to the duration of therapy and not to the nature of the predominant symptom (tremor or hypokinesia and rigidity) or the age of onset of the disease. A relationship was found between the occurrence of response variations and the severity of the disease when levodopa therapy was started. Patients fared worst who were in Hoehn and Yahr stages I and II when levodopa therapy was begun.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3631919     DOI: 10.1002/ana.410220104

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  10 in total

Review 1.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

Authors:  J L Montastruc; O Rascol; J M Senard; A Rascol
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

Review 3.  A risk-benefit assessment of drugs used in the management of Parkinson's disease.

Authors:  I Y Bodagh; D R Robertson
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

Review 4.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

5.  Parkinson's Disease: Initial Treatment with Levodopa or Dopamine Agonists.

Authors:  Stewart A. Factor
Journal:  Curr Treat Options Neurol       Date:  2001-11       Impact factor: 3.598

Review 6.  Does levodopa slow or hasten the rate of progression of Parkinson's disease?

Authors:  Stanley Fahn
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

Review 7.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

8.  Efficacy of sinemet CR4 in subgroups of patients with Parkinson's disease.

Authors:  S A Factor; J R Sanchez-Ramos; W J Weiner; A M Ingenito
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

9.  Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.

Authors:  M W Horstink; J C Zijlmans; J W Pasman; H J Berger; M A van't Hof
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-03       Impact factor: 10.154

10.  Critical role of truncated α-synuclein and aggregates in Parkinson's disease and incidental Lewy body disease.

Authors:  Kavita Prasad; Thomas G Beach; John Hedreen; Eric K Richfield
Journal:  Brain Pathol       Date:  2012-05-23       Impact factor: 6.508

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.